Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review

Table 1

Characteristics of included studies.

Study	Clinicaltrials.gov identifier	Setting	Participants	Intervention	Comparator
ARTEMIS	NCT00258557	Argentina,; Australia,; Austria,; Belgium,; Canada,; Chile,; Costa Rica,; Denmark,; France,; Germany,; Greece,; Guatemala,; Malaysia,; Mexico,; Panama,; Puerto Rico,; Russia,; Singapore,; South Africa,; Spain,; Switzerland,; Taiwan,; Thailand,; United Kingdom, United States	689	DRV/r + TDF/FTC	LPV/r + TDF/FTC
FLAMINGO	NCT00951015	France, Germany,; Italy,; Romania, Russia,; Spain,; Switzerland, United States	286	DRV/r + ABC/3TC or TDF/FTC	DTG + ABC/3TC or TDF/FTC
ACTG 5272	NCT00811954	Puerto Rico,; United States	1809	DRV/RTV + FTC/TDF	ATV/r + FTC/TDF; RAL + FTC/TDF

DRV/r, ritonavir-boosted darunavir; DTG, dolutegravir; ABC, abacavir; 3TC, lamivudine; FTC, emtricitabine; TDF, tenofovir; ATV/r, ritonavir-boosted atazanavir; RAL, raltegravir.